Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody
Background Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our o...
Saved in:
| Published in | Respiratory research Vol. 20; no. 1; pp. 256 - 9 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
12.11.2019
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1465-993X 1465-9921 1465-993X |
| DOI | 10.1186/s12931-019-1231-7 |
Cover
| Abstract | Background
Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death.
Methods
We performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes.
Results
The majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07–34.0,
p
< 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16–0.97,
p
= 0.04, and HR 0.29, 95% CI 0.09–0.81,
p
= 0.03, respectively).
Conclusions
Presentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity. |
|---|---|
| AbstractList | Abstract Background Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death. Methods We performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes. Results The majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07–34.0, p < 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16–0.97, p = 0.04, and HR 0.29, 95% CI 0.09–0.81, p = 0.03, respectively). Conclusions Presentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity. Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death.BACKGROUNDDistinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death.We performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes.METHODSWe performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes.The majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07-34.0, p < 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16-0.97, p = 0.04, and HR 0.29, 95% CI 0.09-0.81, p = 0.03, respectively).RESULTSThe majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07-34.0, p < 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16-0.97, p = 0.04, and HR 0.29, 95% CI 0.09-0.81, p = 0.03, respectively).Presentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity.CONCLUSIONSPresentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity. Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death. We performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes. The majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07-34.0, p < 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16-0.97, p = 0.04, and HR 0.29, 95% CI 0.09-0.81, p = 0.03, respectively). Presentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity. Background Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death. Methods We performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes. Results The majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07-34.0, p < 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16-0.97, p = 0.04, and HR 0.29, 95% CI 0.09-0.81, p = 0.03, respectively). Conclusions Presentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity. Keywords: Interstitial lung disease, Myositis, Antibodies, Interstitial pneumonia with autoimmune features, Connective tissue disease Background Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death. Methods We performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes. Results The majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07–34.0, p < 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16–0.97, p = 0.04, and HR 0.29, 95% CI 0.09–0.81, p = 0.03, respectively). Conclusions Presentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity. Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are well-recognized. However, the association between ILD and the myositis-associated antibodies, including anti-Ro52, is less established. Our objectives were to compare presenting phenotypes of patients with anti-Ro52 alone versus in combination with myositis-specific autoantibodies and to identify predictors of disease progression or death. We performed a retrospective cohort study of 73 adults with ILD and a positive anti-Ro52 antibody. We report clinical features, treatment, and outcomes. The majority of patients with ILD and anti-Ro52 had no established connective tissue disease (78%), and one-third had no rheumatologic symptoms. Thirteen patients (17.8%) required ICU admission for respiratory failure, with 84.6% all-cause mortality. Of the 73 subjects, 85.7% had a negative SS-A, and 49.3% met criteria for idiopathic pneumonia with autoimmune features (IPAF). The 50 patients with anti-Ro52 alone were indistinguishable from patients with anti-Ro52 plus a myositis-specific autoantibody. ICU admission was associated with poor outcomes (HR 12.97, 95% CI 5.07-34.0, p < 0.0001), whereas rheumatologic symptoms or ANA > = 1:320 were associated with better outcomes (HR 0.4, 95% CI 0.16-0.97, p = 0.04, and HR 0.29, 95% CI 0.09-0.81, p = 0.03, respectively). Presentations of ILD with the anti-Ro52 antibody are heterogeneous, and outcomes are similar when compared to anti-Ro52 plus myositis-specific antibodies. Testing for anti-Ro52 may help to phenotype unclassifiable ILD patients, particularly as part of the serologic criteria for IPAF. Further research is needed to investigate treatment of ILD in the setting of anti-Ro52 positivity. |
| ArticleNumber | 256 |
| Audience | Academic |
| Author | Locascio, J. J. Miloslavsky, E. M. Sclafani, A. Montesi, S. B. D’Silva, K. M. Sharma, A. Little, B. P. |
| Author_xml | – sequence: 1 givenname: A. orcidid: 0000-0001-8229-8266 surname: Sclafani fullname: Sclafani, A. email: asclafani1@partners.org organization: Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School – sequence: 2 givenname: K. M. surname: D’Silva fullname: D’Silva, K. M. organization: Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School – sequence: 3 givenname: B. P. surname: Little fullname: Little, B. P. organization: Department of Radiology, Massachusetts General Hospital and Harvard Medical School – sequence: 4 givenname: E. M. surname: Miloslavsky fullname: Miloslavsky, E. M. organization: Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School – sequence: 5 givenname: J. J. surname: Locascio fullname: Locascio, J. J. organization: Biostatistics Center and Department of Neurology, Massachusetts General Hospital and Harvard Medical School – sequence: 6 givenname: A. surname: Sharma fullname: Sharma, A. organization: Department of Radiology, Massachusetts General Hospital and Harvard Medical School – sequence: 7 givenname: S. B. surname: Montesi fullname: Montesi, S. B. organization: Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31718649$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkluL1DAYhousuAf9Ad5IwRtvuiZtDs2NsCweFhYUUfEufM1hNkMnGZNUmX9vuh2XHZFFepHky_s-Sd5-p9WRD95U1XOMzjHu2euEW9HhBmHR4LZM-KPqBBNGGyG670f35sfVaUprhDDvOX1SHXeYFz8RJ9W3T9Ek4zNkF3yqwes6TFmFjUl1sLXz2cSUXXYw1uPkV7V2yUAyt8p8M4_ZNZ8DbWuYcphXQ9C7p9VjC2Myz_bjWfX13dsvlx-a64_vry4vrhvFCM6NwAgNiCLWs0Eo2uKOtx2ygEmnBaVWAUEag7AISl1jqmmrlCYdWMIM9N1ZdbVwdYC13Ea3gbiTAZy8LYS4khCzU6OR2lJuoeOmA0a0EAIzarRmwmiCBzyz2oU1-S3sfsE43gExknPgcglclsDlHLjkxfRmMW2nYWO0KlFGGA9ucrjj3Y1chZ-S9bQVDBfAqz0ghh-TSVluXFJmHMGbMCVZjiFtSaZvi_TlIl1BeY_zNhSimuXygiHeMdLyGXj-D1X5tNk4VRrIulI_MLy4_4S7u_9pkiLgi0DFkFI0Viq3NEwhu_HBdPBfzv9JdP8bUtH6lYlyHaboSxc9YPoNZp7u_Q |
| CitedBy_id | crossref_primary_10_1016_j_semarthrit_2021_01_001 crossref_primary_10_1007_s00408_020_00383_w crossref_primary_10_1016_j_rcreue_2023_08_002 crossref_primary_10_1093_rheumatology_keac339 crossref_primary_10_3390_medicina56090456 crossref_primary_10_1159_000515362 crossref_primary_10_1097_RHU_0000000000002064 crossref_primary_10_1183_13993003_01205_2020 crossref_primary_10_3389_fmed_2023_1068402 crossref_primary_10_1016_j_cellimm_2023_104776 crossref_primary_10_1093_rheumatology_keae104 crossref_primary_10_1186_s13075_023_03141_4 crossref_primary_10_1016_j_arbres_2020_08_020 crossref_primary_10_1016_j_autrev_2024_103600 crossref_primary_10_1016_j_arbr_2021_03_009 crossref_primary_10_1186_s12890_020_01386_2 crossref_primary_10_1007_s10067_020_04984_x crossref_primary_10_1016_j_rcreu_2023_08_003 crossref_primary_10_1097_RHU_0000000000001808 crossref_primary_10_1016_S2213_2600_24_00267_4 crossref_primary_10_1186_s12890_020_01335_z crossref_primary_10_1007_s12016_021_08911_z crossref_primary_10_1038_s41598_022_15321_4 crossref_primary_10_1080_03009742_2021_1887927 crossref_primary_10_1007_s10067_020_05286_y |
| Cites_doi | 10.1186/ar2276 10.1016/j.chest.2018.01.006 10.1136/annrheumdis-2016-210571 10.1136/pgmj.2009.089656 10.2174/157339710791330740 10.1371/journal.pone.0060442 10.3899/jrheum.161480 10.3109/14397595.2015.1091155 10.1002/art.27584 10.1055/s-0034-1371528 10.1016/j.autrev.2009.02.010 10.1002/art.40783 10.1164/rccm.201308-1483ST 10.1186/s13613-018-0433-3 10.1046/j.1365-2249.1997.4081308.x 10.1097/BOR.0000000000000104 10.1007/s00296-009-0884-9 10.1155/2019/9141420 10.1007/s12016-015-8510-y 10.1007/s12026-017-8974-3 10.1097/BOR.0b013e328358bd85 10.1006/jaut.1998.0265 10.1001/jama.2016.0291 10.1016/j.jaad.2010.09.016 10.1002/art.40320 10.1080/03009740510017940 10.3389/fimmu.2019.00444 10.1590/S1806-37132011000100015 10.5402/2012/415272 10.1002/art.38098 10.1016/j.rmed.2007.02.017 10.1016/j.autrev.2011.03.004 10.1080/08916930600623791 10.1136/annrheumdis-2011-200329 10.1002/art.40679 10.1007/s10067-009-1110-6 10.1002/art.34473 10.1183/13993003.00150-2015 10.2169/internalmedicine.49.2889 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1186/s12931-019-1231-7 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1465-993X |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_df57fa37e3a64d999165edd69ed41b18 10.1186/s12931-019-1231-7 PMC6852961 A607364271 31718649 10_1186_s12931_019_1231_7 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIAMS NIH HHS grantid: T32 AR007258 |
| GroupedDBID | --- 0R~ 29P 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM PMFND 7X8 5PM 2VQ ADTOC AHSBF H13 IPNFZ RIG UNPAY |
| ID | FETCH-LOGICAL-c641t-9100b050686b9c52137230fa143d955fca40d1a9f0a230d15d52ccd43af46ea83 |
| IEDL.DBID | DOA |
| ISSN | 1465-993X 1465-9921 |
| IngestDate | Wed Aug 27 01:12:30 EDT 2025 Wed Aug 20 00:14:23 EDT 2025 Tue Sep 30 16:39:35 EDT 2025 Fri Sep 05 10:59:41 EDT 2025 Tue Jun 17 21:30:12 EDT 2025 Tue Jun 10 20:37:47 EDT 2025 Thu Apr 03 06:58:35 EDT 2025 Wed Oct 01 03:23:30 EDT 2025 Thu Apr 24 23:12:31 EDT 2025 Sat Sep 06 07:28:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Antibodies Connective tissue disease Myositis Interstitial lung disease Interstitial pneumonia with autoimmune features |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c641t-9100b050686b9c52137230fa143d955fca40d1a9f0a230d15d52ccd43af46ea83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-8229-8266 |
| OpenAccessLink | https://doaj.org/article/df57fa37e3a64d999165edd69ed41b18 |
| PMID | 31718649 |
| PQID | 2314252182 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_df57fa37e3a64d999165edd69ed41b18 unpaywall_primary_10_1186_s12931_019_1231_7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6852961 proquest_miscellaneous_2314252182 gale_infotracmisc_A607364271 gale_infotracacademiconefile_A607364271 pubmed_primary_31718649 crossref_citationtrail_10_1186_s12931_019_1231_7 crossref_primary_10_1186_s12931_019_1231_7 springer_journals_10_1186_s12931_019_1231_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-11-12 |
| PublicationDateYYYYMMDD | 2019-11-12 |
| PublicationDate_xml | – month: 11 year: 2019 text: 2019-11-12 day: 12 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Respiratory research |
| PublicationTitleAbbrev | Respir Res |
| PublicationTitleAlternate | Respir Res |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | C Cassius (1231_CR10) 2019; 2019 M Infantino (1231_CR35) 2018; 66 WD Gannon (1231_CR39) 2018; 153 C Vuillard (1231_CR11) 2018; 8 J Shi (1231_CR7) 2017; 44 A Fischer (1231_CR33) 2015; 46 Y Koreeda (1231_CR34) 2010; 49 Y Hamaguchi (1231_CR6) 2013; 8 D Aletaha (1231_CR29) 2010; 62 I-J Chen (1231_CR2) 2009; 28 M Satoh (1231_CR9) 2017; 52 F van den Hoogen (1231_CR26) 2013; 65 RW Hallowell (1231_CR3) 2014; 26 Y Yamasaki (1231_CR17) 2016; 26 A Robbins (1231_CR23) 2019; 10 WD Travis (1231_CR25) 2013; 188 B Dasgupta (1231_CR32) 2012; 71 SA Rutjes (1231_CR16) 1997; 109 H Garberg (1231_CR40) 2005; 34 M Petri (1231_CR28) 2012; 64 CH Shiboski (1231_CR27) 2016; 76 JP Ferreira (1231_CR21) 2012; 2012 LA Saketkoo (1231_CR1) 2010; 6 R Hallowell (1231_CR4) 2014; 35 P Novikov (1231_CR37) 2018; 70 P Ghillani (1231_CR24) 2011; 10 D Alarcon-Segovia (1231_CR30) 1987 IE Lundberg (1231_CR31) 2017; 69 EM Wilfong (1231_CR36) 2018; 70 MB Frank (1231_CR14) 1999; 12 M Dugar (1231_CR13) 2010; 86 J Won Huh (1231_CR5) 2007; 101 J Solomon (1231_CR8) 2011; 37 M Koenig (1231_CR15) 2007; 9 J Schulte-Pelkum (1231_CR22) 2009; 8 D Fiorentino (1231_CR18) 2011; 65 R La Corte (1231_CR19) 2006; 39 G Bellani (1231_CR38) 2016; 315 L Casciola-Rosen (1231_CR12) 2012; 24 A Váncsa (1231_CR20) 2009; 29 |
| References_xml | – volume: 9 start-page: R78 issue: 4 year: 2007 ident: 1231_CR15 publication-title: Arthritis Res Ther doi: 10.1186/ar2276 – volume: 153 start-page: 1387 issue: 6 year: 2018 ident: 1231_CR39 publication-title: Chest doi: 10.1016/j.chest.2018.01.006 – volume: 76 start-page: 9 issue: 1 year: 2016 ident: 1231_CR27 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-210571 – volume: 86 start-page: 79 issue: 1012 year: 2010 ident: 1231_CR13 publication-title: Postgrad Med J doi: 10.1136/pgmj.2009.089656 – volume: 6 start-page: 108 issue: 2 year: 2010 ident: 1231_CR1 publication-title: Curr Rheumatol Rev doi: 10.2174/157339710791330740 – volume: 8 start-page: e60442 issue: 4 year: 2013 ident: 1231_CR6 publication-title: PLoS One doi: 10.1371/journal.pone.0060442 – volume-title: Mixed connective tissue disease and anti-nuclear antibodies year: 1987 ident: 1231_CR30 – volume: 44 start-page: 1051 issue: 7 year: 2017 ident: 1231_CR7 publication-title: J Rheumatol doi: 10.3899/jrheum.161480 – volume: 26 start-page: 403 issue: 3 year: 2016 ident: 1231_CR17 publication-title: Mod Rheumatol doi: 10.3109/14397595.2015.1091155 – volume: 62 start-page: 2569 issue: 9 year: 2010 ident: 1231_CR29 publication-title: Arthritis Rheum doi: 10.1002/art.27584 – volume: 35 start-page: 239 issue: 02 year: 2014 ident: 1231_CR4 publication-title: Semin Respir Crit Care Med doi: 10.1055/s-0034-1371528 – volume: 8 start-page: 632 issue: 7 year: 2009 ident: 1231_CR22 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2009.02.010 – volume: 70 start-page: 1901 year: 2018 ident: 1231_CR37 publication-title: Arthritis Rheum doi: 10.1002/art.40783 – volume: 188 start-page: 733 issue: 6 year: 2013 ident: 1231_CR25 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201308-1483ST – volume: 8 start-page: 755 issue: 1 year: 2018 ident: 1231_CR11 publication-title: Ann Intensive Care doi: 10.1186/s13613-018-0433-3 – volume: 109 start-page: 32 issue: 1 year: 1997 ident: 1231_CR16 publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.1997.4081308.x – volume: 26 start-page: 684 issue: 6 year: 2014 ident: 1231_CR3 publication-title: Curr Opin Rheumatol doi: 10.1097/BOR.0000000000000104 – volume: 29 start-page: 989 issue: 9 year: 2009 ident: 1231_CR20 publication-title: Rheumatol Int doi: 10.1007/s00296-009-0884-9 – volume: 2019 start-page: 9141420 issue: 9, article s139 year: 2019 ident: 1231_CR10 publication-title: J Immunol Res doi: 10.1155/2019/9141420 – volume: 52 start-page: 1 issue: 1 year: 2017 ident: 1231_CR9 publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-015-8510-y – volume: 66 start-page: 74 issue: 1 year: 2018 ident: 1231_CR35 publication-title: Immunol Res doi: 10.1007/s12026-017-8974-3 – volume: 24 start-page: 602 issue: 6 year: 2012 ident: 1231_CR12 publication-title: Curr Opin Rheumatol doi: 10.1097/BOR.0b013e328358bd85 – volume: 12 start-page: 137 issue: 2 year: 1999 ident: 1231_CR14 publication-title: J Autoimmun doi: 10.1006/jaut.1998.0265 – volume: 315 start-page: 788 issue: 8 year: 2016 ident: 1231_CR38 publication-title: JAMA doi: 10.1001/jama.2016.0291 – volume: 65 start-page: 25 issue: 1 year: 2011 ident: 1231_CR18 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2010.09.016 – volume: 69 start-page: 2271 issue: 12 year: 2017 ident: 1231_CR31 publication-title: Arthritis Rheum doi: 10.1002/art.40320 – volume: 34 start-page: 49 issue: 1 year: 2005 ident: 1231_CR40 publication-title: Scand J Rheumatol doi: 10.1080/03009740510017940 – volume: 10 start-page: 444 year: 2019 ident: 1231_CR23 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00444 – volume: 37 start-page: 100 issue: 1 year: 2011 ident: 1231_CR8 publication-title: J Bras Pneumol doi: 10.1590/S1806-37132011000100015 – volume: 2012 start-page: 1 issue: 5 year: 2012 ident: 1231_CR21 publication-title: ISRN Rheumatol doi: 10.5402/2012/415272 – volume: 65 start-page: 2737 issue: 11 year: 2013 ident: 1231_CR26 publication-title: Arthritis Rheum doi: 10.1002/art.38098 – volume: 101 start-page: 1761 issue: 8 year: 2007 ident: 1231_CR5 publication-title: Respir Med doi: 10.1016/j.rmed.2007.02.017 – volume: 10 start-page: 509 issue: 9 year: 2011 ident: 1231_CR24 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2011.03.004 – volume: 39 start-page: 249 issue: 3 year: 2006 ident: 1231_CR19 publication-title: Autoimmunity doi: 10.1080/08916930600623791 – volume: 71 start-page: 484 issue: 4 year: 2012 ident: 1231_CR32 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2011-200329 – volume: 70 start-page: 1901 issue: 12 year: 2018 ident: 1231_CR36 publication-title: Arthritis Rheum doi: 10.1002/art.40679 – volume: 28 start-page: 639 issue: 6 year: 2009 ident: 1231_CR2 publication-title: Clin Rheumatol doi: 10.1007/s10067-009-1110-6 – volume: 64 start-page: 2677 issue: 8 year: 2012 ident: 1231_CR28 publication-title: Arthritis Rheum doi: 10.1002/art.34473 – volume: 46 start-page: 1 issue: 4 year: 2015 ident: 1231_CR33 publication-title: Eur Respir J doi: 10.1183/13993003.00150-2015 – volume: 49 start-page: 361 issue: 5 year: 2010 ident: 1231_CR34 publication-title: Intern Med doi: 10.2169/internalmedicine.49.2889 |
| SSID | ssj0017875 |
| Score | 2.4069712 |
| Snippet | Background
Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are... Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are... Background Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase antibodies, are... Abstract Background Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 256 |
| SubjectTerms | Adult Aged Aged, 80 and over Antibodies Autoantibodies Autoantibodies - blood Autoimmunity Cohort Studies Connective tissue disease Development and progression Female Follow-Up Studies Humans Intensive Care Units - trends Interstitial lung disease Interstitial pneumonia with autoimmune features Ligases Lung diseases Lung Diseases, Interstitial - blood Lung Diseases, Interstitial - diagnostic imaging Male Medicine Medicine & Public Health Middle Aged Mortality Myositis Patient Admission - trends Phenotypes Pneumology/Respiratory System Pneumonia Pulmonary fibrosis Respiratory insufficiency Respiratory tract diseases Retrospective Studies Ribonucleoproteins - blood Treatment Outcome Young Adult |
| SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEB9qBa0P4rfRKhEEwRLNx242eRCpYinCiYgnfVs2-6GFkLSXBL3_3plckjZa6osPIbnshtvd-c3ODLP7W4DncY6oSHge5NrYAJ95QLxmAV5OmDgqXE-ms_iUHi7ZxyN-tAXj8VbDADYXhnZ0ntRyVb76dbp-iwr_plf4LH3dkM2ioJiI_fFBXIGraJhiAvmCnSUVEJt8SGxe-NnMNPUM_n_P0-cM1Z-LKKdM6g243lUnav1TleU5Y3VwC24OXqa_v4HFbdiy1R24thjy6Hfh2-ezXUdV46vK-HXXIvhs49fOJw6JFS0iQHD6JU4H_pDH6Wuiy4j39jj4UvPYV11b06-iNut7sDz48PX9YTCcsBDolEUtznRhWISctokUuUZLnggMSZxCJ8rknDutWGgilbtQ4XsTccNjrQ1LlGOpVVlyH7arurIPwTeCyMysLnhkmNIi5y626B7xrHDcZMyDcBxcqQf6cToFo5R9GJKlciMPifKQJA8pPHg5fXKy4d64rPI7kthUkWiz-xf16rsctFAax4VTibCJSpnpfWNujUlza1hURJkHL0jekuCGjdNq2KOAXSSaLLmf4oyIEZuIPNid1USl1LPiZyNiJBXRSrbK1l0jsbE4TRJvvgcPNgia2oy-HPaN5R6IGbZmnZqXVMc_ek7wNKMEOv7v3ohCOerSZWO2NwH13yP86H-M8GPYiXuNi1DpdmG7XXX2Cbp1bfG0V9bf811F0w priority: 102 providerName: Scholars Portal – databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9RAFD5oBS8P4r3RKhEEwRLMJHNJHutiKUJFxErfhslcsLAkpcki_fc9JzsbNyoVH0KymUl2Zs53LsOZ-QLwpqgRFaWos9o6n-G1yIjXLMMjKFewJoxkOsef5dEJ_3QqTiNZNO2F2c7fs0q-78kf0YSXSPvxQt2EWwLtLq3eW8jFlDBA3ImYtPzrYzO3M7Lz_2mDt5zQ7wskpyzpPbizas_N5U-zXG45osMHcD9GkOnBWuQP4YZvH8Ht45gjfwzfv_zaUdT2qWld2q0GBJbv0y6kxA9xQQsEEHjpElU9jTmasSaGg3gezrKvnShSsxo6-tV07vIJnBx-_LY4yuLXEzIrORvQiuV5kwvaAtLUFr10qXC6EQwGSK4WIljDc8dMHXKD9x0TThTWOl6awKU3VfkUdtqu9buQOkVEZd42gjlurKpFKDyGPqJqgnAVTyDfDK62kVqcvnCx1OMUo5J6LQ-N8tAkD60SeDc9cr7m1biu8geS2FSRKLHHG4gUHTVMuyBUMKXypZHcjXGv8M7J2jvOGlYl8JbkrUlxsXHWxP0H2EWiwNIHEq0dzsYUS2BvVhMVzs6KX28Qo6mIVqm1vlv1GhuLJpA48RN4tkbQ1GaM07BvvE5AzbA169S8pD37MfJ9y4qS4_i_-xsU6mho-uvGbH8C6r9H-Pl_vfsF3C1G1WKoXXuwM1ys_EuMzYbm1aiVVxDTLe8 priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Za9wwEB7SDfR46H24TYsLhUKDN77k43FbGkIhIZRu2D4JWUcTYuxl1yakv74ztnazTktKoQ_GWmu8lsajTyNG8xngXZijVUQs93KptIdl5hGvmYeHSVUYFKYj0zk8Sg6m8ZcZm23BySoXZnEVYPYs3c3peDMTvezgGwvyfG-uTD_qs2RvSRMXrYyJ3R8L6Rhrb8F2QoGnEWxPj44n3_tUI2xO3idk9eVoZsOdf_yfwYTV8fr_jt4b09f1rZXr-Oo9uNNWc3F5IcpyYwrbfwAXq873O1fOx21TjOXPa7yQ_187D-G-9XrdSW-mj2BLV4_h9qGN6z-Bk-OrLKhq6YpKuXXb4EP00q2NS5wWC9rUgIPFLRGeXBtX6iTRhcVzc-Z9rVnoirap6VdRq8unMN3__O3TgWe_-ODJJA4aRF7fL3xGaStFLtGziFJcIhmBTp3KGTNSxL4KRG58gddVwBQLpVRxJEycaJFFz2BU1ZV-Aa5KiVxNy4IFKhYyzZkJNbprLCsMU1nsgL96rVxaOnT6KkfJu2VRlvBeZxx1xklnPHXgw_qWec8FcpPwR7KVtSDReHcX6sUPblGBK8NSI6JURyKJVeerM61UkmsVB0WQOfCeLI0T2NBLFTZnArtItF18kiBC4woyDRzYGUgiSMhB9duVrXKqop11la7bJcfGImwTj78Dz3vbXbcZfUvsW5w7kA6setCpYU11dtpxlCcZBfTxubsr--cWHJc36Wx3PUT-ruGX_yT9Cu6GnfkHOAJ2YNQsWv0a_cmmeGPB4Rf8Ymuo priority: 102 providerName: Unpaywall |
| Title | Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody |
| URI | https://link.springer.com/article/10.1186/s12931-019-1231-7 https://www.ncbi.nlm.nih.gov/pubmed/31718649 https://www.proquest.com/docview/2314252182 https://pubmed.ncbi.nlm.nih.gov/PMC6852961 https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-019-1231-7.pdf https://doaj.org/article/df57fa37e3a64d999165edd69ed41b18 |
| UnpaywallVersion | publishedVersion |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: RBZ dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: KQ8 dateStart: 20000101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: KQ8 dateStart: 20000601 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: DOA dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Academic Search Ultimate - eBooks customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: ABDBF dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: DIK dateStart: 20000101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: RPM dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1465-993X dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: M48 dateStart: 20000101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: AAJSJ dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: C6C dateStart: 20000401 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBZbCxt7GLvPWxc8GAxWTC1bsuzHNLSUjYSsLCN7ErIurBDsUtuU_vueYztevEH7sgfLFylEl0_nwpE-EfIpygAVMc-CTBsbwDMPkNcsgMsJE9HctWQ680VytmJf13y9c9QXrgnr6IG7jjsyjgunYmFjlTDTmjPcGpNk1jCa03abL6ixrTPVxw8AhryPYdI0OapQq6HbjNT_8CBGWqgl6_9XJO_opL_XSw5B0yfkcVNcqptrtdns6KXTZ-Rpb1D6064hz8kDW7wgj-Z9yPwl-bn8s8GoqHxVGL9sasCZrfzS-UgXcYXrBQCH_gZmvt-HbNqSYB3Cvb4Izkse-aqpS3zLS3PziqxOT37MzoL-MIVAJ4zWINTCMA857gjJMw1KOxbgfTgF9pLJOHdasdBQlblQwXdDueGR1obFyrHEqjR-TfaKsrBviW8E8pZZnXNqmNIi4y6yYAnxNHfcpMwj4bZzpe6ZxvHAi41sPY40kd14SBgPieMhhUe-DD-57Gg27ip8jCM2FESG7PYD4Eb2uJH34cYjn3G8Jc5jqJxW_XYEaCIyYslpAsIPnDNBPXIwKgnzT4-yP24RIzELF60VtmwqCZUFiYgU-R550yFoqDOYbdA2lnlEjLA1atQ4p7j43dJ_JynGyuF_D7colL3cqe7qs8MBqPf38Lv_0cPv8Vwuyru1Pwdkr75q7Aew4Op8Qh6KtZiQ_eOTxfIc3mbJbNJOYEi_fU8hnTNI91eL5fTXLQR6RYY |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9RAFD7oFmx9EO-NVo0gCJbQXOaSPK5iWdduEW2lb8NkLlpYkrJJkP57z2RnY6NS8SEkmUsyM-c6nJlvAF6lBXJFRouoUNpE-Ewjh2sW4WW5TpPS9mA6i2M2OyXzM3rm93E3m9Xum5Bkr6l7sc7ZQeMsk5v6Ovh-fOA3YSunlJEJbE2n8y_zIXiAPEh9APOvFUcmqEfq_1MfXzFIvy-WHCKmt2G7qy7k5Q-5XF4xSod34Y73JsPpmvz34Iap7sOthY-XP4Cvn37tLqqaUFY6rLsW-2uasLahw4pYucUCyIThEsU-9PGaviS6hnhvz6PPNU1D2bW1eytrffkQTg_fn7ybRf4khUgxkrSo0eK4jKnbDlIWCi12xnHqYSU6S7qg1CpJYp3IwsYS03VCNU2V0iSTljAj8-wRTKq6MrsQau5Ay4wqaaKJVLygNjXoBtG8tFTnJIB4M7hCeZhxd9rFUvTTjZyJNT0E0kM4eggewJuhysUaY-O6wm8dxYaCDh67T6hX34SXNqEt5VZm3GSSEd37wNRozQqjSVImeQCvHb2FE2JsnJJ-LwJ20cFhiSlDzYczM54EsDcqicKnRtkvNxwjXJZbsVaZumsENhbVocPHD-DxmoOGNqPPhn0jRQB8xFujTo1zqvPvPfY3y12gHP-7v-FC4ZVOc92Y7Q-M-u8RfvJf334B27OTxZE4-nD88SnspL2YJShpezBpV515hj5bWz73MvoTyKM2UA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3ba9UwGA-6wdQH8W51agVBcJT1lqR5PF4O8-jGUCd7C2kuOji0h9MW2X_v97U5dVWZ-FB6Sdom-e58yS-EvEgFcEVGRSS0sRFc0whxzSI4HDdpUroeTOfwiB2c5ItTeur3OW02s903KclhTQOiNFXt_sq4QcQLtt-glcIwGKH84YJfJdsFFQyir-3ZbPF5MSYSgB-pT2b-9cWJOepR-__UzReM0-8TJ8fs6Q1yratW6vyHWi4vGKj5LXLTe5bhbGCF2-SKre6QnUOfO79Lvh7_WmlUNaGqTFh3LfTdNmHtQsSNWOPEAWDIcAkqIPS5m74muIlwbs-iTzVNQ9W1Nd6VtTm_R07m7768OYj8rgqRZnnSgnaL4zKmuDSkFBqsd8YhDHEKHCcjKHVa5bFJlHCxgucmoYamWps8Uy5nVhXZfbJV1ZV9SELDEcDM6pImJleaC-pSCy4RLUpHTZEHJN4MrtQechx3vljKPvQomBzoIYEeEukheUBeja-sBryNyyq_RoqNFREqu39Qr79JL3nSOMqdyrjNFMtN7w9TawwT1uRJmRQBeYn0lijQ0Dit_LoE6CJCY8kZAy0IURpPArI7qQmCqCfFzzccI7EIZ69Vtu4aCY0F1YhY-QF5MHDQ2Gbw36BvuQgIn_DWpFPTkurse48DzgpMmsN_9zZcKL0Cai4bs72RUf89wo_-69vPyM7x27n8-P7ow2NyPe2lLAFB2yVb7bqzT8B9a8unXkR_AldyOpo |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Za9wwEB7SDfR46H24TYsLhUKDN77k43FbGkIhIZRu2D4JWUcTYuxl1yakv74ztnazTktKoQ_GWmu8lsajTyNG8xngXZijVUQs93KptIdl5hGvmYeHSVUYFKYj0zk8Sg6m8ZcZm23BySoXZnEVYPYs3c3peDMTvezgGwvyfG-uTD_qs2RvSRMXrYyJ3R8L6Rhrb8F2QoGnEWxPj44n3_tUI2xO3idk9eVoZsOdf_yfwYTV8fr_jt4b09f1rZXr-Oo9uNNWc3F5IcpyYwrbfwAXq873O1fOx21TjOXPa7yQ_187D-G-9XrdSW-mj2BLV4_h9qGN6z-Bk-OrLKhq6YpKuXXb4EP00q2NS5wWC9rUgIPFLRGeXBtX6iTRhcVzc-Z9rVnoirap6VdRq8unMN3__O3TgWe_-ODJJA4aRF7fL3xGaStFLtGziFJcIhmBTp3KGTNSxL4KRG58gddVwBQLpVRxJEycaJFFz2BU1ZV-Aa5KiVxNy4IFKhYyzZkJNbprLCsMU1nsgL96rVxaOnT6KkfJu2VRlvBeZxx1xklnPHXgw_qWec8FcpPwR7KVtSDReHcX6sUPblGBK8NSI6JURyKJVeerM61UkmsVB0WQOfCeLI0T2NBLFTZnArtItF18kiBC4woyDRzYGUgiSMhB9duVrXKqop11la7bJcfGImwTj78Dz3vbXbcZfUvsW5w7kA6setCpYU11dtpxlCcZBfTxubsr--cWHJc36Wx3PUT-ruGX_yT9Cu6GnfkHOAJ2YNQsWv0a_cmmeGPB4Rf8Ymuo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Presentations+and+outcomes+of+interstitial+lung+disease+and+the+anti-Ro52+autoantibody&rft.jtitle=Respiratory+research&rft.au=A.+Sclafani&rft.au=K.+M.+D%E2%80%99Silva&rft.au=B.+P.+Little&rft.au=E.+M.+Miloslavsky&rft.date=2019-11-12&rft.pub=BMC&rft.eissn=1465-993X&rft.volume=20&rft.issue=1&rft.spage=1&rft.epage=9&rft_id=info:doi/10.1186%2Fs12931-019-1231-7&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_df57fa37e3a64d999165edd69ed41b18 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-993X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-993X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-993X&client=summon |